Methods
This retrospective cohort study was conducted in Rambam Health Care Campus, an 1100-bed academic, tertiary, and level 1 trauma center including an intensive burn unit that is an integral part of an 18-bed ICU. The Electronic Health Registry (EHR) files of all patients hospitalized in the ICU with any thermal burn injury between January 1, 2005 and December 31, 2022 were reviewed.
Included patients were those 18 years of age or older with a second-degree burn or higher of a cumulative total body surface area (TBSA) of 10% or higher that were hospitalized in the ICU in our center. We excluded patients with a lack of fully available EHR, or patients who were transferred to an ICU in another facility while hospitalized in our ICU.
Data including patients’ demographics, clinical and laboratory data, microbiologic data and antibiotic and antifungal treatment were collected from the patients’ medical charts. Additional data including vital signs and laboratory results on presentation were mined using the MD-Clone interface (V.3.2 or older). Machine-mined data were assessed for accuracy and relevance by the investigator reviewing the EHR. Patients were followed from admission and up to discharge from ICU. The study was reviewed and approved by the institutional ethics committee (RMB-21–0558).
As per institutional standard of care, all burn victims are hospitalized in single-occupancy chambers and treated in accordance with standard contact precautions, including gloves and disposable gowns. Standard topical wound care aims at early facilitation of autolytic debridement. Superficial exuding wounds are treated with absorbent alginate (Flaminal, Flen Health, Düsseldorf; Germany) and silver-infused dressings (Acticoat, Smith & Nephew, London, UK; and Aquacel Ag, ConvaTec, Reding, UK). Deep wounds are irrigated with Milton sterilizing fluid (1% sodium hypochlorite with 16.5% sodium chloride (Procter & Gamble, Cincinnati, OH, USA)) diluted 1:4 whenever dressing is changed. Deep wounds are surgically debrided as soon as clinical stability allows, with skin allografts or homografts implanted usually during the same operation.
Enteral nutrition is initiated as soon as possible, usually within hours from hospitalization. A team of certified dietitians estimate nutritional needs daily. Caloric intake is estimated using indirect calorimetry for ventilated patients or the Toronto equation for adult burn victims. Protein intake is maintained at 1.5 g/kg–2 g/kg of body weight. Micronutrients and trace elements are supplemented daily. Propranolol is administered, unless contraindicated, in an attempt to counteract hypermetabolism. All nutritional support is in line with the European Society for Clinical Nutrition and Metabolism guidelines for nutritional therapy in major burns.14
Swab cultures from burns are taken whenever there is a clinical impression of wound infection, for example, a new discharge or discoloration samples for pathology and cultures of deep tissue are obtained whenever burn wound excision is performed. All samples are examined by direct smear and cultured for bacterial cultures (blood agar, CHROMagar Orientation plates and thioglycollate). In cases with suspected fungal elements seen on direct smear, swab samples are plated on CHROMagar Candida plates and tissue cultures on Sabouraud Dextrose Agar plates. All described cultures are qualitative. Blood cultures are obtained in any case of clinical suspicion of systemic infection. Blood cultures are incubated using the BD BACTEC FX system and are evaluated by direct smear when positive signals are received. If fungal elements are seen on direct smear, plating on CHROMagar Candida plates and sabouraud dextrose agar plates is performed.
Antibiotic treatment is administered to patients presenting with systemic signs and symptoms of infection, focal infection not related to the wounds or any evidence of local wound infection providing that deep tissue cultures are positive. Patients with colonization of burn wounds with no other signs of infection are not routinely covered for the bacteria isolated. Similarly, antifungal treatment is administered to patients with invasive fungal infection (isolation from any sterile site or evidence of deep tissue invasion). In cases of mere fungal colonization, the decision to administer antifungal treatment is at the discretion of the treating physician based on clinical impression of active infection. There are no institutional guidelines dictating a change in topical or surgical treatment as a result of a positive burn wound swab. No antibiotic and/or antifungal prophylaxis is routinely administered.
Definitions:
Fungal wound colonization: any isolation of fungus from a superficial burn wound culture.
Fungal deep tissue infection: any isolation of fungus from a culture obtained from deep wound tissue (during burn excision).
Invasive fungal infection: any fungal deep tissue infection and/or candidemia during ICU admission.
ICU length of stay: number of days from admission to first discharge from ICU.
Study groups and outcomes:
Our exposure variable of interest was the presence of fungal colonization in burn wounds. Accordingly, we defined two mutually exclusive study groups by the presence or absence of fungal wound colonization (colonization and no-colonization groups). Our primary outcome was defined as the development of invasive fungal infection during ICU stay. Secondary outcomes were candidemia during ICU stay, deep tissue fungal wound infection, ICU length of stay and ICU mortality.
Statistical analysis
Standard descriptive statistics were used to summarize population characteristics. We used a χ2 test for categorical variables, Mann-Whitney’s rank test for non-parametric variables and student’s unpaired t-test for normally distributed continuous variables. Multivariate survival analysis using Cox’s method was performed under the assumption of proportional hazard, with predicting variables displaying high collinearity, determined as Pearson’s r>0.7, excluded from the model. Mortality was considered as a competing risk. A two-sided p<0.05 was considered statistically significant for all tests. Only variables found to be significant predictors of the primary outcome on univariate analysis were included in the multivariate model. All calculations were performed using SPSS software V.29.0 (IBM, Chicago, IL).